STOCK TITAN

TransMedics Reports Second Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

TransMedics Group, Inc. (Nasdaq: TMDX) reported strong financial results for Q2 2024. Total revenue reached $114.3 million, a 118% increase from Q2 2023. The company generated a net income of $12.2 million or $0.35 per diluted share. Key highlights include:

  • Owned 15 aircraft as of June 30, 2024, with two more purchased in July
  • Published 2023 ESG update report
  • Gross margin was 61%, down from 70% in Q2 2023
  • Operating expenses increased to $56.8 million
  • Cash position improved to $362.8 million

TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth compared to the previous year.

TransMedics Group, Inc. (Nasdaq: TMDX) ha riportato risultati finanziari robusti per il secondo trimestre del 2024. I ricavi totali hanno raggiunto $114,3 milioni, con un incremento del 118% rispetto al secondo trimestre del 2023. L'azienda ha generato un utile netto di $12,2 milioni, pari a $0,35 per azione diluita. I principali punti salienti includono:

  • Possesso di 15 aerei al 30 giugno 2024, con due ulteriori acquistati a luglio
  • Pubblicazione del rapporto di aggiornamento ESG 2023
  • Il margine lordo è stato del 61%, in calo rispetto al 70% nel secondo trimestre del 2023
  • Le spese operative sono aumentate a $56,8 milioni
  • La posizione di liquidità è migliorata a $362,8 milioni

TransMedics ha alzato la sua previsione di entrate per l'intero anno 2024 a $425-$445 milioni, rappresentando una crescita del 76-84% rispetto all'anno precedente.

TransMedics Group, Inc. (Nasdaq: TMDX) informó resultados financieros sólidos para el segundo trimestre de 2024. Los ingresos totales alcanzaron $114.3 millones, un incremento del 118% en comparación con el segundo trimestre de 2023. La compañía generó un ingreso neto de $12.2 millones o $0.35 por acción diluida. Los aspectos más destacados incluyen:

  • Poseía 15 aeronaves al 30 de junio de 2024, con dos compradas en julio
  • Publicó el informe de actualización ESG 2023
  • El margen bruto fue del 61%, disminuyendo del 70% en el segundo trimestre de 2023
  • Los gastos operativos aumentaron a $56.8 millones
  • La posición de efectivo mejoró a $362.8 millones

TransMedics aumentó su pronóstico de ingresos para todo el año 2024 a $425-$445 millones, representando un crecimiento del 76-84% en comparación con el año anterior.

TransMedics Group, Inc. (Nasdaq: TMDX)는 2024년 2분기 강력한 재무 결과를 보고했습니다. 총 수익은 1억 1천 4백 30만 달러에 달하여 2023년 2분기 대비 118% 증가했습니다. 회사는 순이익으로 1천 2백 20만 달러 또는 희석 주당 0.35달러를 달성했습니다. 주요 하이라이트는 다음과 같습니다:

  • 2024년 6월 30일 기준 15대의 항공기를 보유하고 있으며, 7월에 2대를 추가로 구매했습니다.
  • 2023년 ESG 업데이트 보고서를 발표했습니다.
  • 총 마진은 61%로, 2023년 2분기 70%에서 감소했습니다.
  • 운영 비용은 5천 6백 80만 달러로 증가했습니다.
  • 현금 포지션은 3억 6천 2백 80만 달러로 개선되었습니다.

TransMedics는 2024년 전체 연도 매출 전망을 4억 2천 5백만에서 4억 4천 5백만 달러로 상향 조정했으며, 이는 전년 대비 76-84% 성장하는 수치입니다.

TransMedics Group, Inc. (Nasdaq: TMDX) a annoncé de solides résultats financiers pour le deuxième trimestre de 2024. Le chiffre d'affaires total a atteint 114,3 millions de dollars, soit une augmentation de 118 % par rapport au deuxième trimestre de 2023. L'entreprise a généré un revenu net de 12,2 millions de dollars, soit 0,35 dollar par action diluée. Les points saillants incluent :

  • Possession de 15 avions au 30 juin 2024, avec deux autres achetés en juillet
  • Publication du rapport de mise à jour ESG 2023
  • La marge brute était de 61 %, en baisse par rapport à 70 % au deuxième trimestre de 2023
  • Les dépenses d'exploitation ont augmenté à 56,8 millions de dollars
  • La position de liquidités s'est améliorée à 362,8 millions de dollars

TransMedics a relevé ses prévisions de chiffre d'affaires pour l'année 2024 à 425-445 millions de dollars, représentant une croissance de 76-84 % par rapport à l'année précédente.

TransMedics Group, Inc. (Nasdaq: TMDX) berichtete über starke finanzielle Ergebnisse für das 2. Quartal 2024. Der Gesamtumsatz belief sich auf 114,3 Millionen USD, was einem Anstieg von 118 % im Vergleich zum 2. Quartal 2023 entspricht. Das Unternehmen erzielte einen Nettoeinkommen von 12,2 Millionen USD oder 0,35 USD pro verwässerter Aktie. Zu den wichtigsten Highlights gehören:

  • Besitz von 15 Flugzeugen zum 30. Juni 2024, mit zwei weiteren im Juli erworben
  • Veröffentlichung des ESG-Updateberichts 2023
  • Bruttomarge lag bei 61 %, im Vergleich zu 70 % im 2. Quartal 2023 gesunken
  • Betriebskosten stiegen auf 56,8 Millionen USD
  • Die Liquiditätsposition verbesserte sich auf 362,8 Millionen USD

TransMedics hat die Gewinnprognose für das gesamte Jahr 2024 auf 425-445 Millionen USD angehoben, was einem Wachstum von 76-84 % im Vergleich zum Vorjahr entspricht.

Positive
  • Total revenue increased by 118% year-over-year to $114.3 million
  • Achieved net income of $12.2 million, compared to a net loss in Q2 2023
  • Raised full-year 2024 revenue guidance to $425-$445 million
  • Cash position improved to $362.8 million
  • Expanded aircraft fleet to support growth
Negative
  • Gross margin decreased from 70% in Q2 2023 to 61% in Q2 2024
  • Operating expenses increased by 51% year-over-year to $56.8 million

Insights

TransMedics' Q2 2024 results demonstrate exceptional growth and a significant turnaround in profitability. The 118% year-over-year revenue increase to $114.3 million is remarkable, driven by the success of their Organ Care System (OCS) and the National OCS Program (NOP). This growth rate far exceeds industry norms for medical technology companies.

The transition from a net loss in Q2 2023 to a net income of $12.2 million in Q2 2024 is a pivotal achievement, representing 10.7% of revenue. This profitability milestone, coupled with a strong cash position of $362.8 million, positions TransMedics well for future investments and growth.

However, the gross margin contraction from 70% to 61% warrants attention. While attributed to a higher proportion of service revenue, investors should monitor this trend to ensure it doesn't impact long-term profitability.

The raised full-year 2024 revenue guidance of $425 million to $445 million implies continued strong growth of 76% to 84%. This upward revision reflects management's confidence in the company's trajectory and market demand for their technologies.

Overall, TransMedics appears to be in a robust growth phase with improving financials, making it an intriguing prospect in the medical technology sector.

TransMedics' Q2 results underscore the growing adoption of their Organ Care System (OCS) technology across multiple organ types. The substantial revenue growth suggests increasing acceptance of their organ transplant therapy in the medical community.

The company's expansion into transplant logistics services, evidenced by their aircraft fleet growth to 15 owned aircraft, represents a strategic move to control the entire organ transplant process. This vertical integration could lead to improved outcomes and efficiency in organ transplantation.

The planned launch of new OCS lung and heart clinical programs in 2025 indicates ongoing innovation and potential market expansion. These initiatives could further solidify TransMedics' position in the organ transplant technology market.

However, the increased operating expenses, particularly in R&D, highlight the need for continued investment to maintain their technological edge. The $56.8 million in operating expenses, up from $37.6 million year-over-year, reflects this commitment to innovation but also impacts near-term profitability.

The publication of their ESG report demonstrates awareness of broader stakeholder concerns, which could be beneficial for long-term sustainability and investor relations.

ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024.

Recent Highlights 

  • Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023
  • Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024
  • Owned 15 total aircraft as of June 30, 2024
  • Purchased two additional aircraft in July 2024
  • Published 2023 Environmental, Social, and Governance ("ESG") update report on TransMedics corporate website

"We set a new high-water mark for the business in the second quarter of 2024, with product and service revenue growth driven by the sustained momentum of OCS NOP and our transplant logistics network," said Waleed Hassanein, MD, President and Chief Executive Officer. "We remain well positioned to successfully execute our 2024 strategy and to launch our new OCS lung and heart clinical programs in 2025."

Second Quarter 2024 Financial Results
Total revenue for the second quarter of 2024 was $114.3 million, a 118% increase compared to $52.5 million in the second quarter of 2023. The increase was driven primarily by the increase in utilization of the Organ Care System ("OCS™") across all three organs through the National OCS Program ("NOP™") as well as additional revenue generated by the launch of TransMedics logistics services.

Gross margin for the second quarter of 2024 was 61%, compared to 70% in the second quarter of 2023. The change from prior year is a result of a higher proportion of service revenue in 2024.

Operating expenses for the second quarter of 2024 were $56.8 million, compared to $37.6 million in the second quarter of 2023. The increase in operating expense was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. Second quarter operating expenses in 2024 included $7.3 million of stock compensation expense compared to $4.9 million of stock compensation expense in the second quarter of 2023.

Net income for the second quarter of 2024 was $12.2 million, or 10.7% of revenue, compared to a net loss of $1.0 million in the second quarter of 2023.

Cash was $362.8 million as of June 30, 2024 compared to $350.2 million as of March 31, 2024.

2024 Financial Outlook
TransMedics is raising its full year 2024 revenue guidance to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue. TransMedics' prior 2024 revenue guidance was $390 million to $400 million.

Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on July 31, 2024. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at www.transmedics.com.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, our full-year guidance, the OCS, NOP, transplant logistics services, and associated new clinical programs, and statements about our operations, financial position, and business plans. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

TransMedics Group, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)








Three Months Ended June 30,


Six Months Ended June 30,



2024


2023


2024


2023

Revenue:









Net product revenue


$                        71,732


$                        42,462


$                      133,057


$                        76,455

Service revenue


42,573


10,003


78,098


17,564

     Total revenue


114,305


52,465


211,155


94,019

Cost of revenue:









Cost of net product revenue


14,470


8,558


28,554


15,864

Cost of service revenue


30,574


7,166


53,378


12,648

     Total cost of revenue


45,044


15,724


81,932


28,512

          Gross profit


69,261


36,741


129,223


65,507










Gross margin


61 %


70 %


61 %


70 %










Operating expenses:









Research, development and clinical trials


13,858


8,291


25,238


14,162

Selling, general and administrative


42,895


29,356


79,056


54,340

     Total operating expenses


56,753


37,647


104,294


68,502

Income (loss) from operations


12,508


(906)


24,929


(2,995)

Other income (expense): 









Interest expense


(3,623)


(2,505)


(7,221)


(3,596)

Interest income and other income (expense) 


3,268


2,431


6,838


2,986

          Total other expense, net


(355)


(74)


(383)


(610)

Income (loss) before income taxes


12,153


(980)


24,546


(3,605)

(Provision) benefit for income taxes 


41


(21)


(155)


(32)

Net income (loss)


$                        12,194


$                        (1,001)


$                        24,391


$                        (3,637)

Net income (loss) per share: 









Basic


$                            0.37


$                          (0.03)


$                            0.74


$                          (0.11)

Diluted


$                            0.35


$                          (0.03)


$                            0.70


$                          (0.11)

Weighted average common shares outstanding: 









Basic


33,119,514


32,545,352


32,939,852


32,403,597

Diluted


35,288,308


32,545,352


34,983,603


32,403,597

 

TransMedics Group, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)




June 30, 2024


December 31, 2023

Assets





Current assets:





Cash


$                      362,751


$                      394,812

Accounts receivable


81,158


63,576

Inventory


48,671


44,235

Prepaid expenses and other current assets


16,685


8,031

           Total current assets


509,265


510,654

Property, plant and equipment, net


229,030


173,941

Operating lease right-of-use assets


5,896


6,546

Restricted cash


500


500

Goodwill


11,549


11,990

Acquired intangible assets, net


2,253


2,354

Other non-current assets


84


62

           Total assets


$                      758,577


$                      706,047

Liabilities and Stockholders' Equity





Current liabilities:





Accounts payable


$                        13,027


$                        12,717

Accrued expenses and other current liabilities


37,716


38,221

Deferred revenue


1,447


1,961

Operating lease liabilities


2,139


2,035

Total current liabilities


54,329


54,934

Convertible senior notes, net


448,534


447,140

Long-term debt, net


59,217


59,064

Operating lease liabilities, net of current portion


6,603


7,707

Total liabilities


568,683


568,845

 Total stockholders' equity


189,894


137,202

 Total liabilities and stockholders' equity


$                      758,577


$                      706,047

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2024-financial-results-302211506.html

SOURCE TransMedics Group, Inc.

FAQ

What was TransMedics' (TMDX) revenue for Q2 2024?

TransMedics reported total revenue of $114.3 million for Q2 2024, representing a 118% increase compared to Q2 2023.

How much net income did TransMedics (TMDX) generate in Q2 2024?

TransMedics generated a net income of $12.2 million, or $0.35 per diluted share, in Q2 2024.

What is TransMedics' (TMDX) updated revenue guidance for 2024?

TransMedics raised its full-year 2024 revenue guidance to be in the range of $425 million to $445 million, representing 76% to 84% growth compared to the previous year.

How many aircraft did TransMedics (TMDX) own as of June 30, 2024?

TransMedics owned 15 total aircraft as of June 30, 2024, and purchased two additional aircraft in July 2024.

TransMedics Group, Inc.

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Stock Data

2.03B
32.48M
3.18%
112.86%
26.74%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ANDOVER